conv.

← The whole story
Business
Novo Nordisk shares plunge 7% as 2030 growth plan disappoints investors

Novo clarifies targets are strategic ambitions, not financial guidance

4 Sep 21 6:30 AM · 5d ago · 1 article · 1 source · development 4 of 5

Novo Nordisk emphasized that the 2030 targets represent strategic ambitions rather than formal financial guidance, and are subject to inherent uncertainty. The company identified 14 major pharmaceutical peers—including Eli Lilly, AstraZeneca, Johnson & Johnson, and Pfizer—against which it will measure its revenue growth performance.

Novo clarifies targets are strategic ambitions, not financial guidance
Yahoo Finance

“The company expects compound annual revenue growth between 2026 and 2030 to be in line with that of its industry peers, while maintaining a broadly stable operating margin.”

Novo Nordisk, Company statement · rss ↗

Novo Nordisk Danish pharmaceutical companyMike DoustdarMike Doustdar Novo Nordisk Chief Executive OfficerEli Lilly & Co. Rival pharmaceutical company

The whole story articlesposts the bright band is this development · numbered dots are the others · click one to jump

Peak 5 pieces in two hours at Sep 21, 5 AM; 16 pieces over 5 days (15 articles · 1 post) Sep 21, 3 AM — 4 pieces · 4 articles — Newswires 4Sep 21, 5 AM — 5 pieces · 4 articles · 1 post — Newswires 4, Mastodon 1Sep 21, 7 AM — 1 piece · 1 article — Newswires 1Sep 21, 9 AM — 2 pieces · 2 articles — Newswires 2Sep 21, 11 AM — 2 pieces · 2 articles — Newswires 2Sep 21, 1 PM — quietSep 21, 3 PM — quietSep 21, 5 PM — quietSep 21, 7 PM — quietSep 21, 9 PM — quietSep 21, 11 PM — quietSep 22, 1 AM — quietSep 22, 3 AM — 1 piece · 1 article — Google News 1Sep 22, 5 AM — 1 piece · 1 article — Google News 1Sep 22, 7 AM — quietSep 22, 9 AM — quietSep 22, 11 AM — quietSep 22, 1 PM — quietSep 22, 3 PM — quietSep 22, 5 PM — quietSep 22, 7 PM — quietSep 22, 9 PM — quietSep 22, 11 PM — quietSep 23, 1 AM — quietSep 23, 3 AM — quietSep 23, 5 AM — quietSep 23, 7 AM — quietSep 23, 9 AM — quietSep 23, 11 AM — quietSep 23, 1 PM — quietSep 23, 3 PM — quietSep 23, 5 PM — quietSep 23, 7 PM — quietSep 23, 9 PM — quietSep 23, 11 PM — quietSep 24, 1 AM — quietSep 24, 3 AM — quietSep 24, 5 AM — quietSep 24, 7 AM — quietSep 24, 9 AM — quietSep 24, 11 AM — quietSep 24, 1 PM — quietSep 24, 3 PM — quietSep 24, 5 PM — quietSep 24, 7 PM — quietSep 24, 9 PM — quietSep 24, 11 PM — quietYesterday, 1 AM — quietYesterday, 3 AM — quietYesterday, 5 AM — quietYesterday, 7 AM — quietYesterday, 9 AM — quietYesterday, 11 AM — quietYesterday, 1 PM — quietYesterday, 3 PM — quietYesterday, 5 PM — quietYesterday, 7 PM — quietYesterday, 9 PM — quietYesterday, 11 PM — quietToday, 1 AM — quietToday, 3 AM — quietToday, 5 AM — quietToday, 7 AM — quietToday, 9 AM — quietToday, 11 AM — quietToday, 1 PM — quiet 1–5
1–5Novo clarifies targets are strategic…
Sep 22Sep 23Sep 24yesterdaynow · 2:30 PM ET

What was reported 1 claim about this development

  1. 1 outlet Novo Nordisk Shares Fall 6% as Drugmaker Outlines Growth Targets Through 2030

    first by Yahoo Finance, 5d ago

All 5 developments of Novo Nordisk shares plunge 7% as 2030 growth plan… →

NewswiresMastodonGoogle News